UBS has upgraded AstraZeneca (NASDAQ:AZN) to buy from neutral, stating it believes the company's in-market growth potential has been underestimated. The investment bank said its forecasts for the ...
Fintel on MSN20h
UBS Upgrades AstraZeneca PLC - Depositary Receipt () (AZN)Fintel reports that on February 13, 2025, UBS upgraded their outlook for AstraZeneca PLC - Depositary Receipt () (NasdaqGS:AZN) from Neutral to Buy. Analyst Price Forecast Suggests 13.43% Upside As of ...
Barclays analyst Duffy Fischer upgraded DuPont de Nemours, Inc. DD from Underweight to Equal-Weight and boosted the price ...
UBS upgraded AstraZeneca (AZN) to Buy from Neutral with a price target of 14,200 GBp, up from 11,500 GBp. The firm cites the company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback